Modality
ADC
MOA
HER2
Target
C5
Pathway
Tau
Psoriasis
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
Jul 2017
→ Feb 2031
Phase 2Current
NCT03550230
2,902 pts·Psoriasis
2018-08→2026-05·Not yet recruiting
NCT04999558
2,418 pts·Psoriasis
2017-07→2031-02·Not yet recruiting
5,320 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-182mo awayPh3 Readout· Psoriasis
2031-02-134.9y awayPh3 Readout· Psoriasis
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2/3
Not yet…
P2/3
Not yet…
Catalysts
Ph3 Readout
2026-05-18 · 2mo away
Psoriasis
Ph3 Readout
2031-02-13 · 4.9y away
Psoriasis
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03550230 | Phase 2/3 | Psoriasis | Not yet recr... | 2902 | PASI75 |
| NCT04999558 | Phase 2/3 | Psoriasis | Not yet recr... | 2418 | Mayo |
Competitors (10)